Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$3.33
-2.9%
$3.45
$1.53
$4.05
$321.33M0.7564,433 shs8,094 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.63
-0.6%
$12.69
$5.22
$27.38
$158.99M0.43145,863 shs75,083 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.36
$1.09
$0.51
$2.45
$61.84M0.8299,498 shs761,522 shs
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
$1.57
+0.6%
$1.56
$0.77
$2.12
$156.65M2.251.58 million shs2.54 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
0.00%-1.74%+3.29%+15.66%+27.11%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-1.86%-4.68%-18.31%+88.79%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.00%+13.33%+33.33%-1.45%+100.00%
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
0.00%-4.85%-19.07%+30.83%+48.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
2.0627 of 5 stars
3.42.00.00.00.01.70.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.982 of 5 stars
3.50.01.72.72.61.71.3
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.3439 of 5 stars
3.65.00.00.02.51.70.6
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
0.5644 of 5 stars
0.01.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
2.80
Moderate Buy$10.40212.22% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50141.49% Upside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.29
Buy$8.00488.24% Upside
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest QNCX, LFVN, SLS, and IVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/4/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
4/4/2025
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $9.00
3/28/2025
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/25/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $4.00
3/24/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$9.95M32.02N/AN/A($1.21) per share-2.75
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.32$2.05 per share6.16
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A$0.69 per shareN/A
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
$1M156.65N/AN/A$0.13 per share12.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$199.34MN/A0.00N/AN/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.30N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$56.83M-$1.39N/AN/AN/AN/A-117.52%-34.22%8/12/2025 (Estimated)
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)

Latest QNCX, LFVN, SLS, and IVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.24-$0.34-$0.10-$0.34N/AN/A
5/13/2025Q1 2025
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/24/2025Q4 2024
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.19-$0.28-$0.09-$0.28N/A$0.17 million
3/20/2025Q4 2024
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
-$0.1067-$0.08+$0.0267-$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.43%N/A26.09%3 Years
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
N/AN/AN/AN/AN/A

Latest QNCX, LFVN, SLS, and IVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/A
0.92
0.92
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.82
4.05
4.05
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
N/A
4.64
4.64

Institutional Ownership

CompanyInstitutional Ownership
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
19.06%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
17.38%

Insider Ownership

CompanyInsider Ownership
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
32.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
20.30%
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
10095.66 million65.05 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6045.47 million36.24 millionOptionable
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
1099.78 million98.38 millionNot Optionable

Recent News About These Companies

Sellas Life Sciences: Tons Of Completed Studies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inventiva stock logo

Inventiva NASDAQ:IVA

$3.41 -0.02 (-0.61%)
As of 06/18/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.63 -0.07 (-0.55%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$12.89 +0.26 (+2.05%)
As of 06/18/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$1.36 0.00 (0.00%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$1.48 +0.12 (+8.46%)
As of 06/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Galena Biopharma stock logo

Galena Biopharma NASDAQ:SLS

$1.57 +0.01 (+0.64%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$1.55 -0.02 (-1.27%)
As of 06/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.